S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.

Elena StrekalovaDmitry MalinErin M M WeisenhornJason D RussellDominik HoelperAayushi JainJoshua J CoonPeter W LewisVincent L Cryns

Published in: Breast cancer research and treatment (2019)

Our findings point to SAM biosynthesis as a unique metabolic vulnerability of CSCs that can be targeted by combining methionine depletion with MAT2A inhibition to eradicate drug-resistant CSCs.

Keyphrases

cancer stem cells
drug resistant
multidrug resistant
climate change
acinetobacter baumannii
cell wall
cancer therapy
cystic fibrosis
amino acid
drug delivery
pseudomonas aeruginosa